Erectile Dysfunction Drugs Market Will Grow Rapidly Owing To Expiration Of Patented Drugs And Enhanced Patient Awareness Till 2022: Grand View Research, Inc.

Grand View Research, Inc. – Market Research And Consulting. has announced the addition of “Global Erectile Dysfunction Drugs Market Analysis And Segment Forecasts To 2022” Market Research report to their Database

The erectile dysfunction drugs market is projected at nearly USD 3.3 billion by 2022. It stood USD 4.3 billion in 2014. The market may face downward trends owing to expiration of patented drugs. Consumer awareness and geriatric population are the primary drivers of the market. Hypertension & stress incidences and poor & inactive lifestyles widen the market’s consumer base.

Full research report on erectile dysfunction drugs market analysis:

However, threats from STDs (sexually transmitted diseases) & counterfeit drugs, and social stigma can restrict the market. Drug distribution techniques like usage of pellets & creams that display improved performance & efficacy should open market avenues.

Zydena, Levitra, Vitaros, Viagra, Cialis, and Stendra are the drug products in the erectile dysfunction drugs market. Among these, Viagra is the most renowned and globally distributed one. Levitra and Cialis are its primary competitors. Viagra dominated the market and was valued over USD 2.4 billion in 2014. Despite its patent expiry in 2019 in the United States, it will contribute over 29% revenues by 2022.

Zydena will grow lucratively in the seven years ahead. This could be attributed to its ‘lesser side effects’ and ‘longer action’ properties. Other drug segments like Stendra and Vitaros are expected to expand following Viagra’s, Cialis’s, and Levitra’s patent expiry. With respect to regions, North America captured 55% of the market in 2013. Extended patent rights of Viagra till 2019 in the United States and novel drugs like Stendra & Zydena are predicted to drive this region.

Request for sample of this research report:

In addition, its well-recognized medical infrastructure and demand for erectile dysfunction products contribute regional sales. The Asian Pacific erectile dysfunction drugs market enjoyed more than 16% shares in 2012. This was due to its profitability for generic drugs and awareness regarding erectile dysfunction. It may grow at 2.4% CAGR from 2015 to 2022.

The same could also be credited to its geriatric population; erectile dysfunction incidences, leading to infections; social stigma; and expanding generic drugs industry. Bayer AG, Pfizer, Inc., Eli Lilly and Company, Apricus Biosciences Inc., and S.K. Chemicals Co. Ltd. are some of the notable players in the worldwide erectile dysfunction drugs market. Pfizer held 40% shares in 2012. It would lose shares in the years ahead. 

View more reports of this category by Grand View Research at:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States